Sun Pharma Initiates Recall of Multiple Eye Drop Brands Across India Over Contamination
Source: ET Real Estate
Arth Insight · What this means for your wallet
- You might lose the money already spent on the recalled eye drops if Sun Pharma does not offer a refund or replacement plan.
- You will incur immediate out-of-pocket expenses to purchase alternative, safe eye drops from another brand.
- Using contaminated eye drops could lead to infections or other eye problems, potentially increasing your medical bills for doctor consultations and new prescriptions.
Sun Pharmaceutical Industries Ltd. has commenced a product withdrawal for several of its eye drop brands in India, citing contamination concerns. This recall affects a range of commonly used ophthalmic solutions, including Depopred, Brinolar, Brinzotim, Lotepred, Nepalact, and Toba-F products.
- ▸Sun Pharmaceutical Industries has initiated a recall of multiple eye drop brands in India.
- ▸The recall is due to a 'contamination scare' affecting product safety.
- ▸A wide range of eye drops, including brands like Depopred, Brinolar, Lotepred, and Nepalact, are impacted.
- ▸Specific details regarding the contamination type, affected batch numbers, and consumer action steps are not yet publicly available.
- ✓Sun Pharmaceutical Industries has initiated a recall of multiple eye drop brands in India.
- ✓The recall is due to a 'contamination scare' affecting product safety.
- ✓A wide range of eye drops, including brands like Depopred, Brinolar, Lotepred, and Nepalact, are impacted.
- ✓Specific details regarding the contamination type, affected batch numbers, and consumer action steps are not yet publicly available.
Sun Pharmaceutical Industries Ltd., a prominent Indian pharmaceutical company, has initiated a widespread recall of numerous eye drop products across India due to a reported contamination scare. The move underscores the company's commitment to patient safety and adherence to regulatory standards, ensuring that potentially compromised medications are removed from circulation.
The recall specifically targets a comprehensive list of eye drop formulations. Consumers and healthcare providers should be aware of the following products identified for withdrawal:
- Depopred2ML
- Brinolar (BKC FREE)
- Brinzotim Eye Drops 5ML BKC FREE
- Lotepred-5ML
- Lotepred 1% Eye Drops SML
- Lotepred LS 0.2%E/D5ML
- Lotepred T
- Nepalact OD Eye Drops 3ML
- Nepalact-Z
- Toba-F
- Nepalact E/D 5ML
A product recall is a critical action taken by manufacturers when products are found to have defects or pose potential health risks, necessitating their removal from the market. In this instance, the 'contamination scare' indicates that the affected eye drops may contain unwanted substances or microbes that could harm users.
While the specific nature of the contamination (e.g., bacterial, fungal, particulate matter) and the exact batch numbers affected have not been detailed in the immediate report, the recall of such a broad range of products highlights the seriousness of the issue. Eye drops are sterile products designed for direct application to the eye, making any contamination a significant health concern that could lead to infections, irritation, or more severe ocular damage.
As of this report, specific instructions for consumers on what to do if they possess these recalled eye drops, such as return procedures or refund information, have not been publicly detailed. It is advisable for individuals currently using any of the listed eye drops to exercise caution and consult their healthcare provider or pharmacist for guidance.
Sun Pharma's prompt action in initiating this withdrawal is a standard industry practice to uphold product quality and patient safety. Regulatory bodies in India will likely monitor the recall process to ensure its effective implementation and to prevent any further distribution of the affected products.
This report is for informational purposes only and should not be considered medical advice. Always consult a healthcare professional for health concerns.
Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.
Frequently Asked Questions
Which company is recalling eye drops in India?
Sun Pharmaceutical Industries Ltd. is recalling eye drop products in India.
What specific eye drop products are being recalled?
The recalled products include Depopred2ML, Brinolar (BKC FREE), Brinzotim Eye Drops 5ML BKC FREE, Lotepred-5ML, Lotepred 1% Eye Drops SML, Lotepred LS 0.2%E/D5ML, Lotepred T, Nepalact OD Eye Drops 3ML, Nepalact-Z, Toba-F, and Nepalact E/D 5ML.
Why are these eye drops being recalled?
The eye drops are being recalled due to a 'contamination scare,' indicating potential safety issues with the products.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about real-estate
AstraZeneca Shares Dip as Breast Cancer Drug Etcamah Fails Key Late-Stage Trial
AstraZeneca's breast cancer treatment, Etcamah, failed to meet its primary goal in a late-stage clinical trial when combined with palbociclib. The setback led to a decline in the company's US-listed shares during aftermarket trading.
Zillow: Global Homebuyers Reduce Activity as Mortgage Rates Climb
A global report by Zillow, cited by Yahoo Finance, indicates a significant slowdown in homebuying activity. This decline is attributed to rising mortgage rates, which are making home loans more expensive for prospective buyers worldwide.
BreakingBlackstone Exits Indian Real Estate, Sells Assets Worth Up to ₹10,800 Crore
Global investment firm Blackstone has reportedly sold Indian real estate assets valued at up to ₹10,800 crore (approximately $1.3 billion). This significant transaction marks a partial exit from its long-standing real estate investments in India, underscoring its strategy to capitalize on profitable ventures.
Related Stories
AstraZeneca Shares Dip as Breast Cancer Drug Etcamah Fails Key Late-Stage Trial
AstraZeneca's breast cancer treatment, Etcamah, failed to meet its primary goal in a late-stage clinical trial when combined with palbociclib. The setback led to a decline in the company's US-listed shares during aftermarket trading.
Zillow: Global Homebuyers Reduce Activity as Mortgage Rates Climb
A global report by Zillow, cited by Yahoo Finance, indicates a significant slowdown in homebuying activity. This decline is attributed to rising mortgage rates, which are making home loans more expensive for prospective buyers worldwide.
BreakingBlackstone Exits Indian Real Estate, Sells Assets Worth Up to ₹10,800 Crore
Global investment firm Blackstone has reportedly sold Indian real estate assets valued at up to ₹10,800 crore (approximately $1.3 billion). This significant transaction marks a partial exit from its long-standing real estate investments in India, underscoring its strategy to capitalize on profitable ventures.
BreakingBad Tenant Costs 45-Year-Old Landlord ₹23.2 Lakh; Is Rental Property Still a Good Bet?
A 45-year-old landlord suffered a significant financial loss of approximately ₹23.2 lakh due to a problematic tenant, covering unpaid rent, legal expenses, and repair costs. Despite this experience, his friends encourage him to invest in another rental property, sparking a debate on the risks versus rewards of real estate investment.